Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children With Influenza

This randomized phase 1b study evaluated the pharmacokinetics/pharmacodynamics of conventional-dose (30–75 mg twice daily [BID]) vs triple-dose (90–225 mg BID; weight-adjusted) oseltamivir for treatment of influenza in severely immunocompromised children <13 years. Oseltamivir carboxylate (OC) C(...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Bautista, Francisco, Engelhard, Dan, Rizzari, Carmelo, Baka, Margarita, Saavedra-Lozano, Jesús, Lopez-Medina, Eduardo, Nasmyth-Miller, Clare, Hernández-Sánchez, Jules, Sturm, Stefan
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Brief Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6809794/
https://ncbi.nlm.nih.gov/pubmed/31660381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz430
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars